

Company Overview

Boston Therapeutics, Inc., (OTC: BTHE), is a clinical stage, pharmaceutical company with a diversified drug development portfolio based on specific expertise in complex carbohydrate chemistry. The Company's lead product addresses unmet needs for the treatment of diabetes. The lead drug candidate is BTI-320, a chewable tablet that works in the gastrointestinal tract to help reduce after-meal sugar spikes. **IPOXYN** is a carbohydrate-based intravenous solution that can potentially prevent necrosis, or cell death, and treat hypoxic conditions such as diabetic foot ulcers.

Highlights

- ✓ **Experienced management:** David Platt, Ph.D., is a chemical engineer, a pioneer in designing drugs made from carbohydrates, and has more than 30 years of experience in the development of therapeutic drugs. He is the inventor or co-inventor on a number of patents, primarily in the field of carbohydrates.
- ✓ **Focus on novel therapeutic opportunities inherent to carbohydrates:** The Company is focused on developing two different carbohydrate-based compounds to better manage blood glucose of diabetics and to treat hypoxia whereby tissues are starved of oxygen associated with heart disease, cancer or trauma.
- ✓ **Products are differentiated and address significant unmet needs:** The lead product candidates are well differentiated formulations that may treat complications of diabetes and hypoxia markets.
- ✓ **A multiple product portfolio with a balanced risk reward profile:** With two lead products at different stages of development, BTHE is positioned in two large and growing chronic disease markets: diabetes and oxygen therapeutics or the ability to get sufficient oxygen supply to support normal metabolic functions, due to a variety of serious medical conditions.
- ✓ **Solid intellectual property and market protection:** The Company has developed a robust intellectual property portfolio comprised of patent applications and trademarks.

Product Portfolio

BTI-320, a new generation of alpha glucosidase inhibitors, works non-systemically in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose. This reduces the amount of glucose available for absorption into the bloodstream. Most anti-diabetes drugs, also called hypoglycemic drugs, force blood sugar levels down systemically by targeting organs such as the pancreas, kidney and liver and the body's cells, increasing the risk of side effects as has been evidenced in FDA findings. In contrast, BTI-320 targets enzymes in the mouth and small intestine to reduce the uptake of glucose during the digestion of carbohydrate foods. This preemptive, non-systemic approach to blood sugar management provides for a stronger safety profile.

IPOXYN is a carbohydrate-based intravenous solution that can potentially prevent necrosis, or cell death, and treat hypoxic conditions such as diabetic foot ulcers and other vascular complications of diabetes. Hypoxia is a condition in which cells lack sufficient oxygen supply to support metabolic function. The IPOXYN carbohydrate molecule contains oxygen rechargeable iron which picks up oxygen in the lungs, is 5,000 times smaller than a red blood cell (RBC), and can reach hypoxic tissue more effectively than RBCs. IPOXYN is stable at room temperature, has a five year shelf life and requires no blood type matching. The Company plans to introduce this product in clinical trials for hypoxic medical conditions. The Company has also developed OXYFEX, a veterinary analog to IPOXYN.


Development Status

- Clinical trials on going in Hong Kong University medical center.
- Clinical trial at Joslin diabetes center pending.
- Submission for approval in China
- Sales of SUGAR BALANCE in Korea and Hong Kong
- Sales of SUGARDOWN in the US for weight loss.

Diabetes: A Growing Epidemic

- According to the International Diabetes Federation, 366 million people are living with diabetes and that number is projected to increase to 551 million by 2030.
- According to Standard & Poor's, the diabetes drug market is estimated to be \$35 billion and is on pace to grow to more than \$58 billion by 2018.
- BTI-320 is pharmacologically differentiated, systemic vs non-systemic from available Postprandial (post meal) Glucose (PPG) drugs.
- BTI-320 has the potential to be an adjunctive therapy when combined with Metformin, the most prescribed diabetes drug in the U.S. with 50 million prescriptions written annually, and represents a compelling value creation opportunity.

Impact of Diabetes



www.bostonti.com

IPOXYN: Market Opportunity

Hypoxia is a condition in which cells lack sufficient oxygen supply to support metabolic function.

Presently, there is no substitute for human blood to deliver oxygen to the body; and transfusions involve certain risks and limitations.

According to a Brown University study, there is a global shortage of transfusion suitable blood of 110 million units, and the need for blood is rising 6-7% annually.

IPOXYN, will compete with existing therapies for the treatment of hypoxia or anti-necrosis that according to market research analysts has a global market opportunity.

Key Management

David Platt, Ph.D.,
Chairman
and CEO

- Expert in complex carbohydrate chemistry and founder of three publicly traded companies
- Founder, former CEO & Chairman of Pro-Pharmaceuticals and SafeScience,
- Co-editor of Carbohydrate Drug Design and Galectins
- Led development of two drug candidates from concept through phase II clinical trials

Stephen Spanos
Chief
Financial
Officer

- Former CFO for Orion Seafood International.
- High level Finance Positions for several small to midsize companies both public and private
- BSBA and MBA from Boston University

Benjamin Rivnay, Ph.D., Chief Scientist

- R&D Director of Formatech, managed more than 50 projects on formulation development
- VP R&D, introduced more than 50 new test products
- Ph.D. in biochemistry, Weizmann Institute, B.Sc. in biology, Tel Aviv University

Contact: David Platt, PhD, CEO
David.platt@bostonti.com
(617-510-2539) (c)